Weekly Digest – December 2024 Weekly Digest – December 2024 27 Dec 2024: DATROWAY® approved in Japan as the first TROP-2 directed therapy for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer Daiichi Sankyo’s DATROWAY® […]
Weekly Digest – December 2024 Weekly Digest – December 2024 23 Dec 2024: Porton Pharma Solutions and Dragon Sail Pharmaceutical form strategic partnership to build a new ecosystem for ADC drug development, production, and supply chain Porton Pharma Solutions and […]
Weekly Digest – December 2024 Weekly Digest – December 2024 23 Dec 2024: OBI Pharma enters collaboration with GlyTech to expand GlycOBI® enabling technologies outreach in Japan and to advance glycan production OBI Pharma, a global oncology company, and GlyTech, […]
Weekly Digest – December 2024 Weekly Digest – December 2024 20 Dec 2024: WuXi Biologics and Hangzhou DAC signed research service agreement with Aadi Bioscience on three novel ADCs WuXi Biologics and Hangzhou DAC Biotechnology have signed a research service […]
Weekly Digest – December 2024 Weekly Digest – December 2024 26 Dec 2024: IND application for a phase I/II clinical study of anti-HER2 bispecific ADC subcutaneous co-formulation JSKN033 was approved Alphamab Oncology has received approval from the CDE of the […]
Weekly Digest – December 2024 Weekly Digest – December 2024 24 Dec 2024: Datopotamab deruxtecan application in the EU for patients with advanced nonsquamous non-small cell lung cancer voluntarily withdrawn AstraZeneca and Daiichi Sankyo have voluntarily withdrawn their marketing authorization […]
